Steven Knox
Gilead Sciences
3
0
3
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (3)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Mahmoud Alalfy
Algazeerah hospital -Location (Giza -Egypt ) and National Research centre egypt
Shared therapeutic areas:
Karim Boudjema, MD, PhD
Rennes University Hospital
Shared therapeutic areas:
Geert Robaeys, prof. dr.
Hasselt University
Shared therapeutic areas:
Shih-Jer Hsu, MD
National Taiwan University Hospital, Yun-Lin Branch
Shared therapeutic areas:
Averell Sherker, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Shared therapeutic areas:
Asem A Elfert, MD
Tanta Faculty of Medicine, Professor
Shared therapeutic areas:
Cheng-Chao Liang, MD
Far Eastern Memorial Hospital
Shared therapeutic areas:
Christine Durand, MD
Johns Hopkins University
Shared therapeutic areas:
Nezam Afdhal, MD
Beth Israel Deaconess Medical Center
Shared therapeutic areas:
Novartis Pharmceuticals
Novartis Pharmaceuticals
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (3)
Showing 3 of 3 trials
Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection
Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection
All 3 trials loaded